Panuveitis
MONDO:0017255A disorder characterized by inflammation of the entire uvea which includes the iris, ciliary body, and choroid. Causes include systemic infections, sarcoidosis, and cancers.
Also known as: diffuse uveitis, panuveitis, panuveitis (disease), total uveitis
10 clinical trials for this condition and its sub-types, 6 tagged with Panuveitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Panuveitis
-
Vogt-Koyanagi-Harada disease 2 trials
-
Infectious panuveitis 1 trial
-
Idiopathic panuveitis 0 trials
1 sub-type
- Idiopathic uveal effusion syndrome 0 trials
-
Sympathetic ophthalmia 0 trials
-
New drug aims to tame eye inflammation in uveitis patients
Disease control Recruiting nowThis study tests a new drug, GenSci048, in people with active non-infectious uveitis, an inflammatory eye disease. The trial will compare two doses of GenSci048 against a placebo to see if it can control the disease and reduce treatment failure. About 111 adults with active uveit…
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for uveitis: Anti-Inflammatory drug tested in chinese patients
Disease control Recruiting nowThis study tests the drug adalimumab (Tebiovio®) in 30 adults with non-infectious uveitis, an inflammatory eye disease. The goal is to see if the drug can control inflammation and prevent treatment failure. Participants will receive injections and be monitored for up to 24 weeks.…
Phase 4 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill could tame eye inflammation without needles
Disease control Recruiting nowThis study tests an oral medication called FXS5626 in 40 adults with active non-infectious uveitis, a condition causing inflammation inside the eye. The goal is to see if the drug can control the disease better than a placebo, reducing the need for other treatments. Participants …
Phase 2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC